

1 **Predictors of all-cause mortality among patients hospitalized with influenza, respiratory**  
2 **syncytial virus, or SARS-CoV-2**

3 **Running title:** Predictors of mortality with respiratory infection

4 **Authors:** Mackenzie A. Hamilton<sup>1,2</sup>, Ying Liu<sup>1</sup>, Andrew Calzavara<sup>1</sup>, Maria E. Sundaram<sup>1,3</sup>,  
5 Mohamed Djebli<sup>1</sup>, Dariya Darvin<sup>2,4</sup>, Stefan Baral<sup>5</sup>, Rafal Kustra<sup>6</sup>, Jeffrey C. Kwong<sup>1,6,7,8,9,10‡</sup>,  
6 Sharmistha Mishra<sup>2,11,12,13‡</sup>

7  
8 **Affiliations:**

9 <sup>1</sup>ICES, Toronto, Canada

10 <sup>2</sup>MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health  
11 Toronto, Toronto, Canada

12 <sup>3</sup>Centre for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, USA

13 <sup>4</sup>Department of Medicine, University of Toronto, Toronto, Canada

14 <sup>5</sup>Department of Epidemiology, John Hopkins Bloomberg School of Public Health, Baltimore, USA

15 <sup>6</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

16 <sup>7</sup>Public Health Ontario, Toronto, Canada

17 <sup>8</sup>Department of Family and Community Medicine, University of Toronto, Toronto, Canada

18 <sup>9</sup>University Health Network, Toronto, Canada

19 <sup>10</sup>Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Canada

20 <sup>11</sup>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

21 <sup>12</sup>Department of Medicine, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada

22 <sup>13</sup>Institute of Medical Sciences, University of Toronto, Canada

23

24 <sup>‡</sup>Authors contributed equally to this manuscript.

25

1 **NOTES**

2 **Acknowledgments**

3 We thank IQVIA Solutions Canada Inc. for use of their Drug Information File. Parts of  
4 this material are based on data and/or information compiled and provided by the Canadian  
5 Institute for Health Information (CIHI) and by Ontario Health (OH). However, the analyses,  
6 conclusions, opinions and statements expressed herein are solely those of the authors, and do not  
7 reflect those of the data sources; no endorsement by CIHI or OH is intended or should be  
8 inferred. JCK is supported by a Clinician-Scientist Award from the University of Toronto  
9 Department of Family and Community Medicine. SM is supported by a Tier 2 Canada Research  
10 Chair in Mathematical Modeling and Program Science.

11

12 **Funding Statement**

13 This work was supported by the Canadian Institutes of Health Research [grant number  
14 VR5-172683 to SM and grant number PJT-159516 to JCK]; and unrestricted research operating  
15 funds from the St. Michael's Hospital Foundation [to SM]. This work was also supported by  
16 ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the  
17 Ministry of Long-Term Care (MLTC). This study was supported by Public Health Ontario, and  
18 the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario's  
19 ongoing response to COVID-19 and its related impacts. The study sponsors did not participate in  
20 the design and conduct of the study; collection, management, analysis and interpretation of the  
21 data; preparation, review or approval of the manuscript; or the decision to submit the manuscript  
22 for publication. The analyses, conclusions, opinions and statements expressed herein are solely

1 those of the authors and do not reflect those of the funding sources; no endorsement by ICES,  
2 MOH, MLTC or OHDP is intended or should be inferred.

3

#### 4 **Ethics Approval**

5 This study used laboratory and health administrative data housed at ICES. ICES is a  
6 prescribed entity under Ontario's Personal Health Information Protection Act (PHIPA). Section  
7 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the  
8 purpose of analysis or compiling statistical information with respect to the management of,  
9 evaluation or monitoring of, the allocation of resources to or planning for all or part of the health  
10 system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other  
11 data, are exempt from REB review. The use of the data in this project is authorized under section  
12 45 and approved by ICES' Privacy and Legal Office. Patient information was de-identified prior  
13 to analysis and distribution.

14

#### 15 **Data Availability**

16 The dataset from this study is held securely in coded form at ICES. While legal data sharing  
17 agreements between ICES and data providers (e.g., healthcare organizations and government)  
18 prohibit ICES from making the dataset publicly available, access may be granted to those who  
19 meet pre-specified criteria for confidential access, available at [www.ices.on.ca/DAS](http://www.ices.on.ca/DAS) (email:  
20 [das@ices.on.ca](mailto:das@ices.on.ca)). The full dataset creation plan and underlying analytic code are available from  
21 the authors upon request, understanding that the computer programs may rely upon coding  
22 templates or macros that are unique to ICES and are therefore either inaccessible or may require  
23 modification.

- 1
- 2 **Conflicts of Interest**
- 3 The authors declare no competing interests that are relevant to the content of this article.

1 **ABSTRACT**

2 **Background:** Shared and divergent predictors of clinical severity across respiratory viruses may  
3 support clinical and community responses in the context of a novel respiratory pathogen.

4 **Methods:** We conducted a retrospective cohort study to identify predictors of 30-day all-cause  
5 mortality following hospitalization with influenza (N=45,749; 2011-09 to 2019-05), respiratory  
6 syncytial virus (RSV; N=24,345; 2011-09 to 2019-04), or severe acute respiratory syndrome  
7 coronavirus 2 (SARS-CoV-2; N=8,988; 2020-03 to 2020-12; pre-vaccine) using population-  
8 based health administrative data from Ontario, Canada. Multivariable modified Poisson  
9 regression was used to assess associations between potential predictors and mortality. We  
10 compared the direction, magnitude, and confidence intervals of risk ratios to identify shared and  
11 divergent predictors of mortality.

12 **Results:** 3,186 (7.0%), 697 (2.9%) and 1,880 (20.9%) patients died within 30 days of hospital  
13 admission with influenza, RSV, and SARS-CoV-2, respectively. Shared predictors of increased  
14 mortality included: older age, male sex, residence in a long-term care home, and chronic kidney  
15 disease. Positive associations between age and mortality were largest for patients with SARS-  
16 CoV-2. Few comorbidities were associated with mortality among patients with SARS-CoV-2 as  
17 compared to those with influenza or RSV.

18 **Conclusions:** Our findings may help identify patients at greatest risk of illness secondary to a  
19 respiratory virus, anticipate hospital resource needs, and prioritize local prevention and  
20 therapeutic strategies to communities with higher prevalence of risk factors.

21

22 **KEY WORDS:** SARS-CoV-2; influenza; respiratory syncytial virus; hospitalization; mortality

23

## 1 BACKGROUND

2 The COVID-19 pandemic has put tremendous strain on hospital systems, and exposed  
3 long-standing issues in healthcare capacity.<sup>1</sup> Knowing who is at highest risk of severe disease  
4 from respiratory viruses may support proactive clinical decision-making, and help distribute  
5 resources to healthcare settings with high prevalence of risk factors.<sup>2</sup> This is particularly useful  
6 in the context of a new and emerging respiratory virus where information and resources are  
7 scarce.<sup>2,3</sup>

8 Several studies have compared shared and divergent predictors of severe disease among  
9 patients with influenza and respiratory syncytial virus (RSV)<sup>4-9</sup>, two respiratory viruses with  
10 high seasonal prevalence prior to the emergence of severe acute respiratory syndrome  
11 coronavirus 2 (SARS-CoV-2). However, few papers have compared predictors of severity across  
12 influenza, RSV, and SARS-CoV-2.

13 Communities are returning to pre-pandemic contact and exposure patterns, which may  
14 increase the risk of all respiratory infections. At the same time, laboratory diagnostic testing is  
15 transitioning to pre-pandemic approaches, where only a subset of hospitalized patients with viral  
16 respiratory or influenza-like illness receive laboratory-confirmed diagnoses.<sup>10</sup> Thus, during  
17 periods of respiratory viral epidemics (particularly with novel emerging pathogens), shared  
18 predictors of severity across the most important respiratory viruses may: 1) reduce morbidity and  
19 mortality by prioritizing preventions (e.g. vaccinations), testing, and access to therapeutics (e.g.  
20 antivirals) and; 2) prepare healthcare settings that will require greater resources based on the  
21 prevalence of the underlying predictors.

22 We conducted an observational study using extensive health administrative data from  
23 Ontario, Canada to identify the direction and magnitude of shared and divergent predictors of 30-

1 day all-cause mortality following hospitalization with influenza, RSV, or SARS-CoV-2 (prior to  
2 vaccine availability or variant emergence).

3

## 4 **METHODS**

### 5 **Study setting and design**

6 We conducted a retrospective cohort study of patients hospitalized with influenza, RSV  
7 or SARS-CoV-2 using population-based laboratory and health administrative data from Ontario,  
8 Canada (population 14.7 million<sup>11</sup>). Ontario's healthcare system provides publicly funded  
9 physician services, laboratory testing, and hospital care for all residents with a provincial health  
10 card. Datasets used in this study were linked using unique encoded identifiers and analyzed at  
11 ICES<sup>12</sup>.

12

### 13 **Case definitions and outcomes**

14 *Hospitalization:* We generated three study cohorts to assess predictors of severe outcomes  
15 among patients hospitalized with influenza, RSV, and SARS-CoV-2 respectively. Patients with  
16 influenza and RSV were identified using hospitalization data from the Canadian Institute for  
17 Health Information's Discharge Abstract Database (DAD) during the 2010-11 to 2018-19  
18 respiratory virus seasons. DAD captures administrative, clinical, and demographic information  
19 on all hospital discharges in Canada. Patients were considered hospitalized with influenza if their  
20 discharge abstract contained any of the following ICD-10 codes: J09, J10.0, J10.1, J10.8, J11.0,  
21 J11.1, or J11.8. Patients were considered hospitalized with RSV if their discharge abstract  
22 contained any of the following ICD-10 codes: J12.1, J20.5, J21.0, or B97.4. Case definitions

1 were validated in Ontario against laboratory confirmation, and showed high specificity  
2 (influenza: 98%; RSV: 99%), and positive predictive values (influenza: 91%; RSV: 91%).<sup>13</sup>

3 We used DAD, the Ontario Laboratories Information System (OLIS), and the Public  
4 Health Case and Contact Management System (CCM) to identify patients hospitalized with  
5 SARS-CoV-2 between March 1 and December 1, 2020. OLIS is an electronic repository of  
6 Ontario's laboratory test results, containing information on laboratory orders, patient  
7 demographics, provider information, and test results. CCM is a central data repository for all  
8 COVID-19 case management, contact management, and reporting in Ontario. Patients were  
9 considered hospitalized with SARS-CoV-2 if: 1) they were documented as hospitalized in DAD  
10 and had a positive polymerase chain reaction test for SARS-CoV-2 within 14 days before or 3  
11 days after hospital admission; or 2) they were documented as hospitalized in CCM.

12 *Mortality:* Our primary outcome of interest was 30-day all-cause mortality following hospital  
13 admission with influenza, RSV or SARS-CoV-2. We used the Registered Persons Database  
14 (RPDB) and CCM to identify patients who died within 30 days of hospital admission. RPDB  
15 contains basic demographic information including age, sex, postal code, and date of death among  
16 all residents with an Ontario health card.

17

## 18 **Inclusion and exclusion criteria**

19 Hospitalized patients were excluded if: they were not eligible for the Ontario Health  
20 Insurance Plan; their birthdate, sex, or postal code was missing from RPDB; their residential  
21 postal code was outside of Ontario; they were older than 105 years according to their birthdate in  
22 RPDB; or their recorded death date predated hospital admission (**Figure 1**). Only one  
23 hospitalization per patient was included (per season for influenza and RSV, and overall for



1 SARS-CoV-2). Among patients hospitalized with influenza or RSV, we included the first  
2 hospital admission of the season. Among patients hospitalized with SARS-CoV-2, we included  
3 any hospitalization that resulted in death within 30 days of admission, or the first admission if no  
4 other admission was associated with 30-day mortality. Variation in inclusion criteria were due to  
5 suspected differences in hospital admission and discharge behavior across virus cohorts. For  
6 example, early in the pandemic, evidence suggested that patients hospitalized with SARS-CoV-2  
7 had a relatively high likelihood of readmission within 60 days of discharge.<sup>14</sup> Patients  
8 hospitalized with influenza or RSV were excluded if they were hospitalized outside of the  
9 respective respiratory virus season. Respiratory virus seasonality was defined as November to  
10 May for influenza, and November to April for RSV to align with case definitions from Hamilton  
11 et al.<sup>13</sup>, and to create the most inclusive time frame to capture seasonal virus activity in Ontario.<sup>15</sup>

### 13 **Predictors of 30-day all-cause mortality**

14 We selected potential predictors of 30-day all-cause mortality *a priori*. Variables were  
15 considered if they had documented or suspected associations with respiratory virus acquisition or  
16 severity, or healthcare access in peer-reviewed, published literature.

17 *Demographic Characteristics:* We used data from RPDB to describe pertinent individual-level  
18 demographic characteristics including age, sex, and residence in rural neighbourhoods.<sup>16</sup> Rural  
19 neighbourhoods were defined as those outside commuting zones of population centres (i.e.  
20 centres with more than 10,000 residents).

21 We used aggregated 2016 Canadian census data to describe neighbourhood-level social  
22 determinants of health associated with risk of respiratory virus acquisition<sup>17-19</sup>, access to care,  
23 and discrimination within health care settings<sup>20,21</sup> including: income<sup>22</sup>, household size<sup>23</sup>, and

1 “ethnic concentration”<sup>24</sup> (herein referred to as percent racialized). Neighbourhood-level variables  
2 were categorized into quintiles (i.e. 1 = 20% of neighbourhoods with lowest values; 5 = 20% of  
3 neighbourhoods with highest values). Patients were assigned a quintile according to their  
4 residential postal code. We describe derivation of the neighbourhood-level determinants of  
5 health in depth in **Supplementary text**.

6 *Underlying Health Conditions:* Pertinent underlying health conditions included: asthma, chronic  
7 obstructive pulmonary disease (COPD), hypertension, cardiac ischemic disease, congestive heart  
8 failure, stroke, dementia or frailty, chronic kidney disease, advanced liver disease, and  
9 immunosuppression (i.e. patients with a cancer diagnosis in the past 5 years, human  
10 immunodeficiency virus, solid organ or bone marrow transplant, or another immunodeficiency  
11 condition).<sup>25,26</sup> We used validated case definitions and health administrative data to classify each  
12 individual-level health condition. Case definitions and validity are described in detail in  
13 **Supplementary Table 1**.

14 *Other Covariates:* Other predictors of severe outcomes included residence in a long-term care  
15 home (LTCH)<sup>27,28</sup>, and seasonal immunization against influenza<sup>29-31</sup>. We used the Chronic Care  
16 Reporting System, pharmacist billing claims in the Ontario Drug Benefits Database (ODB), and  
17 physician billing claims in the Ontario Health Insurance Plan (OHIP) database to determine  
18 whether individuals resided in a LTCH. We used ODB and OHIP to identify patients vaccinated  
19 against influenza between October 1 of the season of hospital admission and 14 days prior to  
20 admission. Relevant vaccination claim codes and drug identification numbers are outlined in  
21 **Supplementary Table 2**.

22  
23 **Statistical analyses**

1 Data processing and analyses were conducted using SAS version 9.4 (SAS Institute,  
2 Cary, NC). Frequencies and proportions were used to describe the distribution of risk factors  
3 among individuals hospitalized with influenza, RSV, or SARS-CoV-2. Modified Poisson  
4 regression (i.e. Poisson regression with a robust error variance) was used to assess the  
5 association between predictors and 30-day all-cause mortality. Modified Poisson regression was  
6 used over logistic regression to estimate risk ratios and avoid misinterpretation of odds ratios  
7 obtained from logistic regression.<sup>32</sup> We calculated unadjusted and adjusted relative risk of dying  
8 within 30 days of hospital admission per predictor among each hospitalization cohort. Adjusted  
9 models included all other predictors. We qualitatively compared the direction, magnitude, and  
10 95% confidence interval of associations among respective cohorts of hospitalized patients to  
11 identify shared and divergent predictors of 30-day all-cause mortality.

12

## 13 **RESULTS**

### 14 **Characteristics of patients hospitalized with influenza, RSV or SARS-CoV-2**

15 We observed 45,749 influenza hospitalizations, 24,345 RSV hospitalizations, and 8,988  
16 SARS-CoV-2 hospitalizations after applying inclusion and exclusion criteria (**Figure 1**). Patients  
17 hospitalized with RSV were younger than patients hospitalized with influenza or SARS-CoV-2  
18 (median age RSV patients = 1 year; median age influenza patients = 71 years; median age  
19 SARS-CoV-2 patients = 70 years). Only 47% of RSV patients presented with at least one  
20 comorbidity as compared to 84% of influenza patients and 82% of SARS-CoV-2 patients. **Table**  
21 **1** compares additional characteristics of hospitalized patients by virus and 30-day all-cause  
22 mortality.

23

## 1 **Common predictors of 30-day all-cause mortality**

2 Patients hospitalized with SARS-CoV-2 had the highest crude 30-day all-cause mortality  
3 rate (SARS-CoV-2 crude mortality rate = 20.9%; influenza crude mortality rate = 7.0%; RSV  
4 crude mortality rate = 2.9%).

5 In unadjusted models, shared predictors of mortality included: older age, residence in a  
6 LTCH, immunization against seasonal influenza, COPD, cardiac ischemic disease, congestive  
7 heart failure, hypertension, diabetes, dementia/frailty, stroke, and chronic kidney disease (**Figure**  
8 **2, Supplementary Table 3**). Larger magnitudes of association between older age and mortality  
9 were observed among patients hospitalized with SARS-CoV-2 [unadjusted relative risk (RR)  
10 among 85+ versus 50-64 = 4.88; 95% confidence interval (CI) = 4.16 to 5.72] versus influenza  
11 (unadjusted RR among 85+ versus 50-64 = 2.99; 95% CI = 2.65 to 3.37) or RSV (unadjusted RR  
12 among 85+ versus 50-64 = 2.53; 95% CI = 1.93 to 3.32). All other shared predictors of mortality  
13 showed larger magnitudes of association among patients hospitalized with RSV (**Figure 2**).

14 In adjusted models, shared predictors of mortality included: older age, male sex,  
15 residence in a LTCH, and chronic kidney disease (**Figure 2, Supplementary Table 4**). Similar  
16 to unadjusted models, we observed larger magnitudes of association between older age and 30-  
17 day all-cause mortality among patients hospitalized with SARS-CoV-2 [SARS-CoV-2: adjusted  
18 RR (95% CI) 85+ versus 50-64 = 3.64 (3.08 to 4.30); influenza: adjusted RR (95% CI) 85+  
19 versus 50-64 = 2.18 (1.91 to 2.48); RSV: adjusted RR (95% CI) 85+ versus 50-64 = 2.16 (1.60 to  
20 2.92)]. The magnitude and direction of associations between male sex, residence in a LTCH, and  
21 chronic kidney disease, and mortality were similar among patients hospitalized with all three  
22 viruses.

23

## 1 **Notable differences among predictors of 30-day all-cause mortality**

2 Rural residence was associated with increased 30-day all-cause mortality among patients  
3 hospitalized with RSV (adjusted RR = 1.52, 95% CI = 1.09 to 2.12) and SARS-CoV-2 (adjusted  
4 RR = 1.27, 95% CI = 1.01 to 1.61), but not among patients hospitalized with influenza (adjusted  
5 RR = 1.00, 95% CI = 0.87 to 1.14). Immunization against seasonal influenza was associated with  
6 decreased 30-day all-cause mortality among patients hospitalized with influenza (adjusted RR =  
7 0.89, 95% CI = 0.83 to 0.96) but not patients hospitalized with RSV (adjusted RR = 1.09, 95%  
8 CI = 0.93 to 1.28) or SARS-CoV-2 (adjusted RR = 1.04, 95% CI = 0.95 to 1.13). Finally, cardiac  
9 ischemic disease, congestive heart failure, dementia/frailty, and immunosuppression were  
10 associated with increased all-cause mortality among patients hospitalized with influenza and  
11 RSV after adjustment for all other predictors, but not among patients hospitalized with SARS-  
12 CoV-2.

## 14 **DISCUSSION**

15 We identified shared and divergent predictors of mortality among patients hospitalized with  
16 influenza, RSV, or SARS-CoV-2 using population-based health administrative data from  
17 Ontario, Canada. In multivariable models, common predictors of 30-day all-cause mortality  
18 following hospitalization included older age, male sex, residence in a LTCH, and chronic kidney  
19 disease.

20 Older age and male sex were predictive of increased mortality across all respiratory virus  
21 cohorts, which aligns with numerous studies from high-income countries<sup>4-9,33-35</sup>, and confirms  
22 the need to consider age and sex in clinical practice. The magnitude of association between older  
23 age and mortality was largest among patients with SARS-CoV-2, confirming robust evidence

1 that age is an important predictor of severity among COVID-19 patients, and should be used to  
2 guide targeted COVID-19 preventions and therapeutics.<sup>35,36</sup>

3 Residence in a LTCH was also a common predictor of 30-day all-cause mortality; however,  
4 associations were weaker among patients hospitalized with SARS-CoV-2. Differences in  
5 magnitudes of association may be due to greater selection bias of LTCH residents hospitalized  
6 with SARS-CoV-2 in comparison to those with influenza or RSV. For example, in Ontario, less  
7 than one quarter of COVID-19-positive LTCH residents were hospitalized prior to death,  
8 compared to nearly 80% of COVID-19-positive community residents during the first wave of the  
9 pandemic<sup>37</sup>. It has been suggested that LTCH residents with SARS-CoV-2 may have been less  
10 likely to be hospitalized due to advanced care directives and/or informal policies that  
11 discouraged transfers of critically ill residents<sup>37-39</sup>. The difference in hospitalizations prior to  
12 death narrowed in the pre-vaccination second wave of the pandemic in Ontario<sup>37</sup> suggesting that  
13 the selection biases may have been specific to wave 1, and may not be reflective of past  
14 influenza or RSV seasonal epidemics.

15 Similar to previous studies<sup>40</sup>, chronic kidney disease increased risk of 30-day all-cause  
16 mortality with similar magnitudes of effect among patients hospitalized with influenza, RSV or  
17 SARS-CoV-2. Several other comorbidities were important predictors of mortality among  
18 patients with influenza or RSV, but not SARS-CoV-2 despite their known associations with  
19 SARS-CoV-2 severity.<sup>26</sup> These comorbidities may have been associated with mortality among  
20 influenza and RSV patients, but not SARS-CoV-2 patients due to: 1) smaller sample size of the  
21 latter; 2) greater hospitalization rates of less severe patients with comorbidities who were  
22 infected with SARS-CoV-2 (i.e. selective hospitalization of patients with comorbidities due to  
23 limited understanding of the virus and disease trajectory); and/or 3) true clinical differences

1 between patients requiring hospitalization with SARS-CoV-2 versus seasonal influenza or  
2 RSV.<sup>41-43</sup> Moreover, age may act as an effect measure modifier on the relationship between  
3 comorbidities and mortality due to SARS-CoV-2. More research is needed to compare the  
4 immunological and clinical disease progression of influenza, RSV, and SARS-CoV-2 to better  
5 explain observed differences in risk by comorbidity.

6 We did not observe associations between area-level social determinants of health and 30-  
7 day all-cause mortality following hospitalization with all three viruses, despite their associations  
8 with infection transmission risk.<sup>17-21</sup> Lack of associations may be due to misclassification of  
9 neighbourhood-level social determinants of health (as these metrics were derived from the 2016  
10 census), ecological fallacy, or adjustment of mediators in the causal pathway between income,  
11 household size, or racialization, and 30-day all-cause mortality.

12 This study is limited by potential misclassification of influenza and RSV cases, as we  
13 identified patients using their hospitalization discharge codes rather than diagnostic test results.  
14 However, case definitions were validated against a population of hospitalized patients who  
15 received diagnostic testing for influenza or RSV in the Ontario population.<sup>13</sup> The case definitions  
16 had high specificity (influenza = 98%; RSV = 99%) and positive predictive values (influenza =  
17 91%; RSV = 91%). Thus, misclassification of influenza and RSV hospitalization is likely rare.  
18 Moreover, the use of influenza and RSV case definitions allowed us to obtain hospitalization  
19 data across more respiratory virus seasons, increasing the generalizability of our findings.

20 Moreover, the study outcome as defined may capture deaths attributable to the virus or  
21 deaths in the context of an incidental infection (i.e., death *with* the virus). The additional public  
22 health dataset available for SARS-CoV-2 (i.e., CCM) allowed us to compare death outcomes of  
23 hospitalized patients with SARS-CoV-2 (this dataset documents whether cause of death was due

1 to, or likely due to COVID-19) to their mortality within 30 days of hospitalization in health  
2 administrative data (i.e., RPDB). 30-day all-cause mortality had 97% positive predictive value  
3 against death due to COVID-19 in CCM. Thus, we expect 3% of outcomes to potentially reflect  
4 deaths with SARS-CoV-2. In the absence of approaches to adequately address this  
5 misclassification for all viruses, we acknowledge the small bias as an important limitation.

6 This study is also limited by a lack of data on other important predictors of respiratory  
7 infection severity such as pregnancy<sup>44,45</sup>, obesity<sup>46</sup>, and individual-level social determinants (e.g.  
8 economic marginalization and racialization), which are known to mediate quality of hospitalized  
9 care and rates of respiratory virus infection<sup>17-21</sup>. When using our results to inform prioritization  
10 of services, or to develop clinical prediction tools, we must consider these limitations so that  
11 other at-risk patients do not fall through the cracks.

12 Finally, to provide insights on shared predictors of mortality in the context of a novel,  
13 emerging pathogen, we purposefully restricted the study period of SARS-CoV-2 to exclude  
14 hospitalizations of patients vaccinated against SARS-CoV-2, or those with SARS-CoV-2  
15 variants. Future work would benefit from comparisons of predictors of mortality among patients  
16 hospitalized with influenza, RSV or SARS-CoV-2 variants and/or breakthrough infections in the  
17 context of a vaccine to better inform responses to re-emerging respiratory pathogens.

18 Our results add to the growing literature base comparing similarities and differences in  
19 clinical disease progression of patients hospitalized with influenza and SARS-CoV-2<sup>41-43</sup>, and  
20 have three important implications for clinical care and health systems. First, shared predictors of  
21 mortality could be used to identify, target, and prioritize hospitalized patients who are at greatest  
22 risk of death for prevention (e.g. vaccines), testing (e.g. rapid tests) and therapeutics (e.g.  
23 antivirals) in the context of a novel respiratory pathogen. Second, the underlying prevalence of



1 shared predictors in a given geography could help prepare health systems for, and efficiently  
2 allocate health resources during, emergence of a novel respiratory pathogen. Finally, differences  
3 in observed predictors of mortality across the three viruses signal the importance of sufficient  
4 virus-specific laboratory testing to ensure at-risk individuals are not left behind.

## 5 **Conclusion**

6 We identified common predictors of 30-day all-cause mortality following hospitalization  
7 with SARS-CoV-2, influenza, or RSV in a population-based cohort from Ontario, Canada.  
8 Shared predictors of mortality may help identify patients at greatest risk for syndromic clinical  
9 management of illness from respiratory viruses, anticipate local resource needs (e.g. for  
10 communities and hospitals), and prioritize prevention and therapeutic strategies during rapid  
11 emergence of respiratory viruses.

## 13 **AUTHOR CONTRIBUTION STATEMENT**

14 MAH, MD, MS, RK, JCK and SM were involved in conceptualization, design and  
15 methodological decisions of the study. JCK and SM led supervision, administration and funding  
16 acquisition for the study. Supervision was supported by RK and SB. YL curated and cleaned data  
17 for analyses of patients hospitalized with influenza and RSV supported by AC, and AC curated  
18 and cleaned data of patients hospitalized with SARS-CoV-2. MAH conducted the formal  
19 analysis and investigation of predictors of mortality among patients hospitalized with influenza  
20 and RSV, supported by MD. MS conducted the formal analysis and investigation of predictors of  
21 mortality among patients hospitalized with SARS-CoV-2. DD led the visualization of analyses  
22 supported by MAH. MAH drafted the original manuscript and led the review and editing  
23 process. All authors edited and/or reviewed, and approved the final manuscript.

## 1 REFERENCES

- 2 1. Sen-Crowe B, Sutherland M, McKenney M, Elkbuli A. A Closer Look Into Global  
3 Hospital Beds Capacity and Resource Shortages During the COVID-19 Pandemic. *J Surg*  
4 *Res.* 2021;260:56.
- 5 2. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and  
6 prognosis of covid-19: systematic review and critical appraisal. *BMJ.* 2020;369:26.
- 7 3. Williams RD, Markus AF, Yang C, et al. Seek COVER: using a disease proxy to rapidly  
8 develop and validate a personalized risk calculator for COVID-19 outcomes in an  
9 international network. *BMC Med Res Methodol* 2022 221. 2022;22(1):1-13.
- 10 4. Ackerson B, Tseng HF, Sy LS, et al. Severe Morbidity and Mortality Associated With  
11 Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. *Clin*  
12 *Infect Dis.* 2019;69(2):197-203.
- 13 5. Atamna A, Babich T, Froimovici D, et al. Morbidity and mortality of respiratory syncytial  
14 virus infection in hospitalized adults: Comparison with seasonal influenza. *Int J Infect Dis.*  
15 2021;103:489-493.
- 16 6. Jansen AGSC, Sanders EAM, Hoes AW, Van Loon AM, Hak E. Influenza- and  
17 respiratory syncytial virus-associated mortality and hospitalisations. *Eur Respir J.*  
18 2007;30(6):1158-1166.
- 19 7. Kwon YS, Park SH, Kim MA, et al. Risk of mortality associated with respiratory syncytial  
20 virus and influenza infection in adults. *BMC Infect Dis.* 2017;17(1).
- 21 8. Zhang Y, Wang Y, Zhao J, et al. Severity and mortality of respiratory syncytial virus vs  
22 influenza A infection in hospitalized adults in China. *Influenza Other Respi Viruses.*  
23 2020;14(5):483-490.

- 1 9. Cohen R, Babushkin F, Geller K, Finn T. Characteristics of hospitalized adult patients  
2 with laboratory documented Influenza A, B and Respiratory Syncytial Virus - A single  
3 center retrospective observational study. *PLoS One*. 2019;14(3).
- 4 10. Gostin LO. Life After the COVID-19 Pandemic. *JAMA Heal Forum*. 2022;3(2):e220323-  
5 e220323. doi:10.1001/JAMAHEALTHFORUM.2022.0323
- 6 11. Statistics Canada. *Table 17-10-0009-01 Population Estimates, Quarterly*.
- 7 12. ICES. Data and Privacy.. <https://www.ices.on.ca/Data-and-Privacy> Accessed January 12,  
8 2022
- 9 13. Hamilton MA, Calzavara A, Emerson SD, et al. Validating International Classification of  
10 Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus  
11 hospitalizations. *PLoS One*. 2021;16:1-12.
- 12 14. Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC. Readmission and Death After Initial  
13 Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System.  
14 *JAMA*. 2021;325(3):304-306.
- 15 15. Public Health Ontario. Ontario Respiratory Pathogen Bulletin.  
16 [https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/respiratory-](https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/respiratory-pathogens-weekly)  
17 [pathogens-weekly](https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/respiratory-pathogens-weekly) Accessed January 12, 2022
- 18 16. Wilson R, Rourke J, Oandasan IF, Bosco C. Progress made on access to rural health care  
19 in Canada. *Can Fam Physician*. 2020;66.
- 20 17. Upshaw TL, Brown C, Smith R, Perri M, Ziegler C, Pinto AD. Social determinants of  
21 COVID-19 incidence and outcomes: A rapid review. *PLoS One*. 2021;16(3):e0248336.
- 22 18. Foley D, Best E, Reid N, Berry M (Mary) J. Respiratory health inequality starts early: The  
23 impact of social determinants on the aetiology and severity of bronchiolitis in infancy. *J*

- 1        *Paediatr Child Health*. 2019;55(5):528-532.
- 2    19.    Martin LJ, Chen Y, Serrano-Lomelin J, Talbot J, Yasui Y. Higher levels of social and  
3        material deprivation are associated with higher rates of influenza-like illness-related  
4        emergency department visits: Edmonton, Alberta, 2004-2014. *Public Health*.  
5        2020;189:117-122.
- 6    20.    Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 — A  
7        Dangerous Convergence for Black Americans. *N Engl J Med*. 2020;383(12):e77.
- 8    21.    Siegel M, Critchfield-Jain I, Boykin M, Owens A. Actual Racial/Ethnic Disparities in  
9        COVID-19 Mortality for the Non-Hispanic Black Compared to Non-Hispanic White  
10       Population in 35 US States and Their Association with Structural Racism. *J Racial Ethn*  
11       *Heal Disparities*. 2021:1-13.
- 12    22.    Statistics Canada. Total income. Dictionary, Census of Population, 2016. 2017.  
13       <https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/pop123-eng.cfm> Accessed  
14       January 28, 2022
- 15    23.    Statistics Canada. Private dwelling. Dictionary, Census of Population, 2016. 2017.  
16       [https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/dwelling-logements005-](https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/dwelling-logements005-eng.cfm)  
17       [eng.cfm](https://www12.statcan.gc.ca/census-recensement/2016/ref/dict/dwelling-logements005-eng.cfm) Accessed January 28, 2022
- 18    24.    Matheson FI, van Ingen T. *2016 Ontario Marginalization Index: User Guide.*; 2018.
- 19    25.    Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated  
20       influenza illness: systematic review and meta-analysis. *BMJ*. 2013;347(7923).
- 21    26.    Chidambaram V, Tun NL, Haque WZ, et al. Factors associated with disease severity and  
22       mortality among patients with COVID-19: A systematic review and meta-analysis. *PLoS*  
23       *One*. 2020;15(11).

- 1 27. Childs A, Zullo AR, Joyce NR, et al. The burden of respiratory infections among older  
2 adults in long-term care: A systematic review. *BMC Geriatr.* 2019;19(1):1-10.
- 3 28. Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the  
4 institutionalized elderly: clinical and epidemiologic findings. *J Am Geriatr Soc.*  
5 1992;40(2):115-119.
- 6 29. Chung H, Buchan SA, Campigotto A, et al. Influenza Vaccine Effectiveness Against All-  
7 Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011  
8 to 2015–2016 Seasons in Ontario, Canada. *Clin Infect Dis.* 2021;73(5):e1191-e1199.
- 9 30. Bechini A, Ninci A, Del Riccio M, et al. Impact of Influenza Vaccination on All-Cause  
10 Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A  
11 Meta-Analysis of Observational Studies. *Vaccines.* 2020;8(2).
- 12 31. Wilcox CR, Islam N, Dambha-Miller H. Association between influenza vaccination and  
13 hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort  
14 study. *BMJ Open Respir Res.* 2021;8(1):e000857.
- 15 32. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary  
16 Data. *Am J Epidemiol.* 2004;159(7):702-706.
- 17 33. Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality:  
18 Systematic review and meta-analysis. *Pediatr Pulmonol.* 2017;52(4):556.
- 19 34. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The Effect of Age on Mortality  
20 in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. *J Am Med Dir*  
21 *Assoc.* 2020;21(7):915. 5
- 22 35. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and  
23 Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-

- 1           Analysis. *Intervirology*. 2021;64(1):36-47.
- 2   36.   O’Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity  
3           patterns of SARS-CoV-2. *Nat* 2020 5907844. 2020;590(7844):140-145.
- 4   37.   Brown KA, Daneman N, Buchan SA, Chan AK, Stall NM. Variation in Care of  
5           Community and Nursing Home Residents Who Died of COVID-19 in Ontario, Canada. *J*  
6           *Am Med Dir Assoc*. 2021;22(6):1149-1150.
- 7   38.   Reith T. “No benefit” to sending seniors ill with COVID-19 to hospital, some nursing  
8           homes tell loved ones. CBC News. 2020. [https://www.cbc.ca/news/health/covid-19-long-](https://www.cbc.ca/news/health/covid-19-long-term-care-1.5519657)  
9           term-care-1.5519657 Accessed May 3, 2022
- 10 39.   Ontario Long Term Care Commission Meeting with Chartwell Retirement Residences.  
11           2020. [http://www.ltccommission-](http://www.ltccommission-commissionsld.ca/transcripts/pdf/Chartwell_Retirement_Residences_Transcript_October_09_2020.pdf)  
12           commissionsld.ca/transcripts/pdf/Chartwell\_Retirement\_Residences\_Transcript\_October\_  
13           09\_2020.pdf Accessed May 3, 2022
- 14 40.   Su G, Iwagami M, Qin X, et al. Kidney disease and mortality in patients with respiratory  
15           tract infections: a systematic review and meta-analysis. *Clin Kidney J*. 2021;14(2):602-  
16           611.
- 17 41.   Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and  
18           mortality of COVID-19 and seasonal influenza: a nationwide, population-based  
19           retrospective cohort study. *Lancet Respir Med*. 2021;9(3):251-259.
- 20 42.   Laris-González A, Avilés-Robles M, Domínguez-Barrera C, et al. Influenza vs. COVID-  
21           19: Comparison of Clinical Characteristics and Outcomes in Pediatric Patients in Mexico  
22           City. *Front Pediatr*. 2021;9:676611.
- 23 43.   Hedberg P, Karlsson Valik J, Van Der Werff S, et al. Clinical phenotypes and outcomes of

- 1 SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study  
2 using complete hospital data. *Thorax*. 2022;77(2):1-10.
- 3 44. Mertz D, Lo CKF, Lytvyn L, et al. Pregnancy as a risk factor for severe influenza  
4 infection: An individual participant data meta-analysis. *BMC Infect Dis*. 2019;19(1):1-10.
- 5 45. Villar J, Ariff S, Gunier RB, et al. Maternal and Neonatal Morbidity and Mortality Among  
6 Pregnant Women With and Without COVID-19 Infection: The INTERCOVID  
7 Multinational Cohort Study. *JAMA Pediatr*. 2021;175(8):817-826.
- 8 46. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global  
9 perspective on the epidemiology and biological relationships. *Obes Rev*.  
10 2020;21(11):e13128.  
11

1 **Table 1.** Descriptive characteristics of patients hospitalized with influenza, respiratory syncytial  
 2 virus, or SARS-CoV-2.

Characteristic	Influenza		RSV		SARS-CoV-2	
	n (%)	Deaths (%)	n (%)	Deaths (%)	n (%)	Deaths (%)
<b>Total</b>	45,749	3,186	24,345	697	8,988	1,880
<b>Demographics</b>						
Age group						
0-4	4,863 (10.6)	11 (0.3)	17,157 (70.5)	20 (2.9)	65 (0.7)	0 (0)
5-19	2,363 (5.2)	12 (0.4)	557 (2.3)	7 (1.0)	67 (0.8)	0 (0)
20-49	4,466 (9.8)	95 (3.0)	421 (1.7)	19 (2.7)	1,367 (15.2)	36 (1.9)
50-64	6,519 (14.2)	305 (9.6)	969 (4.0)	59 (8.5)	2,150 (23.9)	186 (9.9)
65-74	7,030 (15.4)	466 (14.6)	1,298 (5.3)	88 (12.6)	1,674 (18.6)	347 (18.5)
75-84	9,981 (21.8)	827 (26.0)	1,837 (7.5)	190 (27.3)	1,826 (20.3)	535 (28.5)
≥85	10,527 (23.0)	1,470 (46.1)	2,106 (8.7)	314 (45.1)	1,839 (20.5)	776 (41.3)
Male sex	21,831 (47.7)	1,551 (48.7)	12,603 (51.8)	302 (43.3)	4,768 (53.1)	1,029 (54.7)
Living in rural area	3,818 (8.3)	260 (8.2)	2,243 (9.2)	41 (5.9)	253 (2.8)	53 (2.8)
Long-term care resident	3,048 (6.7)	814 (25.5)	721 (3.0)	168 (24.1)	1,355 (15.1)	620 (33.0)
Immunized against seasonal influenza	14,718 (32.2)	1,083 (34.0)	4,106 (16.9)	287 (41.2)	3,077 (34.2)	694 (36.9)
<b>Underlying Health Conditions</b>						
Asthma	12,838 (28.1)	762 (23.9)	6,630 (27.2)	190 (27.3)	1,777 (19.8)	345 (18.4)
COPD	11,924 (26.1)	1,183 (37.1)	2,593 (10.7)	273 (39.2)	1,098 (12.2)	342 (18.2)
Cardiac ischemic disease	9,301 (20.3)	1,044 (32.8)	1,717 (7.1)	225 (32.3)	1,063 (11.8)	341 (18.1)
Congestive heart failure	12,240 (26.8)	1,507 (47.3)	2,769 (11.4)	349 (50.1)	1,609 (17.9)	540 (28.7)
Hypertension	28,811 (63.0)	2,644 (83.0)	5,379 (22.1)	580 (83.2)	5,912 (65.8)	1,590 (84.6)



Diabetes	16,036 (35.1)	1,373 (43.1)	2,828 (11.6)	295 (42.3)	3,795 (42.2)	996 (53.0)
Dementia/frailty	11,149 (24.4)	1,557 (48.9)	2,451 (10.1)	368 (52.8)	2,604 (29.0)	940 (50.0)
Stroke	3,999 (8.7)	445 (14.0)	738 (3.0)	102 (14.6)	679 (7.6)	224 (11.9)
Chronic kidney disease	9,729 (21.3)	1,091 (34.2)	2,007 (8.2)	250 (35.9)	2,120 (23.6)	711 (37.8)
Immunosuppression	7,222 (15.8)	578 (18.1)	1,936 (8.0)	174 (25.0)	602 (6.7)	146 (7.8)
Advanced liver disease	1,305 (2.9)	115 (3.6)	246 (1.0)	26 (3.7)	252 (2.8)	47 (2.5)
<b>Neighbourhood-level social determinants of health<sup>g</sup></b>						
<b>Income quintile</b>						
Missing	149 (0.3)	11 (0.3)	147 (0.6)	1-5 <sup>†</sup>	67 (0.8)	10 (0.5)
1 (lowest income)	12,199 (26.7)	773 (24.3)	5,967 (24.5)	202 (29.0)	2,617 (29.1)	541 (28.8)
2	10,187 (22.3)	798 (25.0)	5,162 (21.2)	164 (23.5)	2,081 (23.2)	483 (25.7)
3	8,802 (19.2)	597 (18.7)	4,754 (19.5)	113 (16.2)	1,823 (20.3)	404 (21.5)
4	7,564 (16.5)	482 (15.1)	4,527 (18.6)	110 (15.8)	1,293 (14.4)	234 (12.5)
5 (highest income)	6,848 (15.0)	525 (16.5)	3,788 (15.6)	103-107 <sup>†</sup>	1,107 (12.3)	208 (11.1)
<b>Household size quintile</b>						
Missing	416 (0.9)	30 (0.9)	380 (1.6)	10 (1.4)	139 (1.6)	34 (1.8)
1 (smallest household size)	11,947 (26.1)	911 (28.6)	4,614 (19.0)	202 (29.0)	1,729 (19.2)	410 (21.8)
2	8,319 (18.2)	636 (20.0)	4,507 (18.5)	129 (18.5)	1,168 (13.0)	253 (13.5)
3	6,173 (13.5)	445 (14.0)	3,512 (14.4)	105 (15.1)	905 (10.1)	205 (10.9)
4	9,605 (21.0)	665 (20.9)	5,821 (23.9)	155 (22.2)	2,156 (24.0)	457 (24.3)
5 (largest household size)	9,289 (20.3)	499 (15.7)	5,511 (22.6)	96 (13.8)	2,891 (32.2)	521 (27.7)
<b>Percent racialized quintile</b>						
Missing	420 (0.9)	27 (0.8)	328 (1.3)	7 (1.0)	98 (1.1)	19 (1.0)
1 (least percent racialized)	7,035 (15.4)	512 (16.1)	3,573 (14.7)	85 (12.2)	579 (6.4)	115 (6.1)

2	7,482 (16.4)	540 (16.9)	4,124 (16.9)	99 (14.2)	843 (9.4)	212 (11.3)
3	8,179 (17.9)	601 (18.9)	4,510 (18.5)	135 (19.4)	1,355 (15.1)	340 (18.1)
4	9,578 (20.9)	743 (23.3)	5,039 (20.7)	174 (25.0)	1,914 (21.3)	380 (20.2)
5 (most percent racialized)	13,055 (28.5)	763 (23.9)	6,771 (27.8)	197 (28.3)	4,199 (46.7)	814 (43.3)


- 
- 1 RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COPD, chronic
  - 2 obstructive pulmonary disease.
  - 3 †Cells with less than five patients have been suppressed to prevent individual identification.

1 **Figure 1. Study cohorts and exclusions.** A) Influenza hospitalization cohort. B) RSV  
2 hospitalization cohort. C) SARS-CoV-2 hospitalization cohort. Exclusions were made in the  
3 order in which they appear. RSV, respiratory syncytial virus; SARS-CoV-2, severe acute  
4 respiratory syndrome coronavirus 2; OHIP, Ontario health insurance plan.  
5 †Influenza and RSV hospitalizations prior to the 2010-11 respiratory virus season were excluded  
6 to reduce selection bias due to changes in testing behavior following the H1N1 influenza  
7 epidemic in 2009-10.  
8 ‡Virus seasonality was defined as November through May, and November through April for  
9 influenza and RSV, respectively.

10

11 **Figure 2. Unadjusted and adjusted predictors of 30-day all-cause mortality among patients**  
12 **hospitalized with influenza, RSV or SARS-CoV-2.** Modified Poisson regression was used to  
13 calculate associations between predictors and 30-day all-cause mortality. Adjusted models  
14 included all predictors. Influenza and RSV adjusted models additionally included season of  
15 hospital admission. Associations are presented as risk ratios (points) and 95% confidence  
16 intervals (error bars). RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory  
17 syndrome coronavirus 2; COPD, chronic obstructive pulmonary disease; CI, confidence interval.

## (A) Influenza Cohort




### Patients Excluded:

- 59 patients: with missing birthdate, sex, or postal code; from out of province; greater than 105 years old; or with death dates listed before hospital admission
- 86 patients who were not eligible for OHIP

### Hospitalizations Excluded

- 1,526 secondary hospitalizations within the same season
- 9,427 hospitalizations prior to 2010-11 influenza season<sup>a</sup>
- 1,385 hospitalizations outside of the influenza respiratory virus season<sup>b</sup>

## (B) RSV Cohort




### Patients Excluded:

- 147 patients: with missing birthdate, sex, or postal code; from out of province; greater than 105 years old; or with death dates listed before hospital admission
- 291 patients who were not eligible for OHIP

### Hospitalizations Excluded

- 1,092 secondary hospitalizations within the same season
- 10,683 hospitalizations prior to 2010-11 influenza season<sup>a</sup>
- 1,069 hospitalizations outside of the RSV respiratory virus season<sup>b</sup>


## (C) SARS-CoV-2 Cohort




### Hospitalizations and Patients Excluded

- 333 secondary hospitalizations
- 13 patients with missing birthdate, sex, or postal code; from out of province; greater than 105 years old; or with death dates listed before hospital admission
- 6,268 duplicate hospitalizations (recorded in CCM and CIHI-DAD)


### Demographics



### Underlying health conditions



### Social determinants of health



Risk Ratio and 95% CI

◆ Influenza ◆ RSV ◆ SARS-CoV-2